These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31447275)

  • 41. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
    Huang X; Wang Q; Chen W; Ren G; Liu Z
    Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone].
    Zhao Q; Wang L; Song P; Li F; Zhou X; Yu Y; An Z; Wang X; Zhai Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):283-7. PubMed ID: 27093989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bortezomib, Melphalan, Dexamethasone: A New Standard of Care for AL Amyloidosis?
    Pratt G
    J Clin Oncol; 2020 Oct; 38(28):3243-3244. PubMed ID: 32749940
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of systemic AL amyloidosis: about 25 cases].
    Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
    Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.
    Sun CY; Li JY; Chu ZB; Zhang L; Chen L; Hu Y
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28706008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis.
    Gran C; Borg Bruchfeld J; Ellin F; Nahi H
    Acta Haematol; 2020; 143(5):500-503. PubMed ID: 31896106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Options for Chemotherapy and Scoring Response and Relapse.
    Varga C; Chaulagain C
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1115-1131. PubMed ID: 33099428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
    Wang X; Li Y; Yan X
    Biomed Res Int; 2016; 2016():6848902. PubMed ID: 26949704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
    Jelinek T; Kryukova E; Kufova Z; Kryukov F; Hajek R
    Hematol Oncol; 2017 Dec; 35(4):408-419. PubMed ID: 27647123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study.
    Miyazaki K; Suzuki K
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):413-422.e5. PubMed ID: 31023593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
    Ravichandran S; Cohen OC; Law S; Sachchithanantham S; Mahmood S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2021 Aug; 194(3):587-597. PubMed ID: 34189728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
    Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
    Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atraumatic Splenic Rupture Due to Ectopic Extramedullary Hematopoiesis after Autologous Stem Cell Transplantation in a Patient with AL Amyloidosis.
    Sato S; Tamai Y; Okada S; Kannbe E; Takeda K; Tanaka E
    Intern Med; 2018 Feb; 57(3):399-402. PubMed ID: 29093392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.